DE60116302T2 - Verfahren zum Behandeln seborrhoischer Dermatitis - Google Patents
Verfahren zum Behandeln seborrhoischer Dermatitis Download PDFInfo
- Publication number
- DE60116302T2 DE60116302T2 DE60116302T DE60116302T DE60116302T2 DE 60116302 T2 DE60116302 T2 DE 60116302T2 DE 60116302 T DE60116302 T DE 60116302T DE 60116302 T DE60116302 T DE 60116302T DE 60116302 T2 DE60116302 T2 DE 60116302T2
- Authority
- DE
- Germany
- Prior art keywords
- ivermectin
- seborrheic dermatitis
- lotion
- cream
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 208000008742 seborrheic dermatitis Diseases 0.000 title claims abstract description 21
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title abstract description 5
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims abstract description 15
- 229960002418 ivermectin Drugs 0.000 claims abstract description 15
- 239000006210 lotion Substances 0.000 claims abstract description 10
- 239000006071 cream Substances 0.000 claims abstract description 9
- 239000003937 drug carrier Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000000699 topical effect Effects 0.000 claims description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 238000012423 maintenance Methods 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 description 7
- 201000004624 Dermatitis Diseases 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010048259 Zinc deficiency Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000011102 Thera Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000004013 groin Anatomy 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- -1 ketanazole Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 208000002042 onchocerciasis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- WQVJHHACXVLGBL-GOVYWFKWSA-N polymyxin B1 Polymers N1C(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)CCCC[C@H](C)CC)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1CC1=CC=CC=C1 WQVJHHACXVLGBL-GOVYWFKWSA-N 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- VIDTVPHHDGRGAF-UHFFFAOYSA-N selenium sulfide Chemical compound [Se]=S VIDTVPHHDGRGAF-UHFFFAOYSA-N 0.000 description 1
- 229960005265 selenium sulfide Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/605,747 US6319945B1 (en) | 2000-06-29 | 2000-06-29 | Method of treatment of seborrheic dermatitis |
| US605747 | 2000-06-29 | ||
| PCT/US2001/041159 WO2002002056A2 (en) | 2000-06-29 | 2001-06-27 | Method of treatment of seborrheic dermatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60116302D1 DE60116302D1 (de) | 2006-02-02 |
| DE60116302T2 true DE60116302T2 (de) | 2006-08-10 |
Family
ID=24425042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60116302T Expired - Lifetime DE60116302T2 (de) | 2000-06-29 | 2001-06-27 | Verfahren zum Behandeln seborrhoischer Dermatitis |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6319945B1 (enExample) |
| EP (1) | EP1294375B1 (enExample) |
| JP (1) | JP3802485B2 (enExample) |
| CN (1) | CN1171588C (enExample) |
| AT (1) | ATE314068T1 (enExample) |
| AU (1) | AU2002216748A1 (enExample) |
| CA (1) | CA2384448C (enExample) |
| DE (1) | DE60116302T2 (enExample) |
| ES (1) | ES2252312T3 (enExample) |
| WO (1) | WO2002002056A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7897559B2 (en) * | 2000-06-29 | 2011-03-01 | Parks L Dean | Dermatological composition and kit containing avermectin compound for treating dermatological conditions |
| US6399651B1 (en) * | 2000-06-29 | 2002-06-04 | L. Dean Parks | Method of treating dermatoses using avermectin compound |
| AU2003247735B2 (en) | 2002-06-26 | 2010-03-11 | Avery Dennison Corporation | Oriented films comprising polypropylene / olefin elastomer blends |
| BRPI0410503B8 (pt) * | 2003-04-24 | 2021-05-25 | Galderma Sa | composição tópica e uso da composição |
| FR2854074B1 (fr) * | 2003-04-24 | 2007-11-23 | Galderma Res & Dev | Utilisation de l'ivermectine pour le traitement de desordres dermatologiques |
| FR2867684B1 (fr) * | 2004-03-18 | 2006-05-05 | Galderma Sa | Gel creme contenant de l'ivermectine |
| FR2894823B1 (fr) * | 2005-12-20 | 2008-02-29 | Galderma Sa | Composition de type emulsion inverse comprenant de l'ivermectine, et ses utilisations en cosmetique et en dermatologie |
| CN103121320B (zh) | 2006-06-14 | 2015-06-24 | 艾利丹尼森公司 | 可顺应和可冲切的轴向定向的标签原料和标签及制备方法 |
| BRPI0713492A2 (pt) | 2006-06-20 | 2012-01-24 | Avery Dennison Corp | filme polimérico de multi-camadas para rotulagem de adesivos de derretimento a quente e etiqueta e rótulo dos mesmos |
| CA2666365C (en) * | 2006-10-12 | 2016-08-09 | Topaz Pharmaceuticals Llc | Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice |
| US8901163B2 (en) | 2007-01-03 | 2014-12-02 | Galderma S.A. | Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound |
| WO2012054331A1 (en) | 2010-10-20 | 2012-04-26 | Galderma S.A. | Method of treating otitis externa using macrocyclic lactone compound |
| EP2629772B1 (en) | 2010-10-20 | 2016-05-18 | Galderma S.A. | Ivermectin for use in the treatment of hemorrhoids |
| US9782425B2 (en) | 2013-07-08 | 2017-10-10 | Galderma S.A. | Treatment of papulopustular rosacea with ivermectin |
| US9233118B2 (en) | 2013-07-08 | 2016-01-12 | Galderma S.A. | Treatment of papulopustular rosacea with ivermectin |
| AU2015270854B2 (en) | 2014-06-02 | 2018-08-02 | Avery Dennison Corporation | Films with enhanced scuff resistance, clarity, and conformability |
| CN110604741A (zh) * | 2018-06-15 | 2019-12-24 | 瑞恩生化科技有限公司 | 抑制皮肤细胞增生的组合物及其应用 |
| EP4062907A1 (fr) | 2021-03-23 | 2022-09-28 | Substipharm | Formulation par voie orale d'ivermectine et utilisations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439924A (en) * | 1991-12-23 | 1995-08-08 | Virbac, Inc. | Systemic control of parasites |
| US5877295A (en) * | 1992-09-30 | 1999-03-02 | The Center For Blood Research | Antibodies which bind a subpopulation of Mac-1 (CD11b/CD18) molecules which mediate neutrophil adhesion to ICAM-1 and fibrinogen |
| DE4328689A1 (de) * | 1993-08-26 | 1995-03-02 | Beiersdorf Ag | Verfahren zur Detektion und Zählung von Mikroorganismen |
| US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
| US5654312A (en) * | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
| WO1997044034A1 (en) * | 1996-05-20 | 1997-11-27 | Otsuka Pharmaceutical Co., Ltd. | Remedy for rosacea |
| US5952372A (en) * | 1998-09-17 | 1999-09-14 | Mcdaniel; William Robert | Method for treating rosacea using oral or topical ivermectin |
| KR100315465B1 (ko) * | 1998-11-23 | 2002-02-19 | 성재갑 | 수용성고분자와알코올을포함하는주사제용동물구충제조성물 |
-
2000
- 2000-06-29 US US09/605,747 patent/US6319945B1/en not_active Expired - Lifetime
-
2001
- 2001-06-27 EP EP01984091A patent/EP1294375B1/en not_active Expired - Lifetime
- 2001-06-27 CN CNB018018572A patent/CN1171588C/zh not_active Expired - Fee Related
- 2001-06-27 DE DE60116302T patent/DE60116302T2/de not_active Expired - Lifetime
- 2001-06-27 AU AU2002216748A patent/AU2002216748A1/en not_active Abandoned
- 2001-06-27 CA CA002384448A patent/CA2384448C/en not_active Expired - Fee Related
- 2001-06-27 WO PCT/US2001/041159 patent/WO2002002056A2/en not_active Ceased
- 2001-06-27 JP JP2002506679A patent/JP3802485B2/ja not_active Expired - Fee Related
- 2001-06-27 AT AT01984091T patent/ATE314068T1/de not_active IP Right Cessation
- 2001-06-27 ES ES01984091T patent/ES2252312T3/es not_active Expired - Lifetime
- 2001-10-12 US US09/976,914 patent/US6433006B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2384448C (en) | 2008-09-16 |
| EP1294375A2 (en) | 2003-03-26 |
| US6319945B1 (en) | 2001-11-20 |
| AU2002216748A1 (en) | 2002-01-14 |
| JP2004501939A (ja) | 2004-01-22 |
| WO2002002056A3 (en) | 2002-03-28 |
| WO2002002056A2 (en) | 2002-01-10 |
| CN1171588C (zh) | 2004-10-20 |
| ES2252312T3 (es) | 2006-05-16 |
| EP1294375A4 (en) | 2004-06-09 |
| ATE314068T1 (de) | 2006-01-15 |
| DE60116302D1 (de) | 2006-02-02 |
| CA2384448A1 (en) | 2002-01-10 |
| JP3802485B2 (ja) | 2006-07-26 |
| US20020019354A1 (en) | 2002-02-14 |
| EP1294375B1 (en) | 2005-12-28 |
| CN1383379A (zh) | 2002-12-04 |
| US6433006B2 (en) | 2002-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60116302T2 (de) | Verfahren zum Behandeln seborrhoischer Dermatitis | |
| DE60218508T2 (de) | Verfahren zur behandlung von akne vulgaris mit einer avermectin-verbindung | |
| DE69520041T2 (de) | Arzneimittel auf der basis von einer synergistischen mischung von metronidazol und clinamicin | |
| EP0907351B1 (de) | Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der "cellulite" | |
| DE69818806T2 (de) | Antimikrobielle kosmetische präparate | |
| DE60217900T2 (de) | Verfahren zur behandlung von dermatosen mit einer avermectin-verbindung | |
| DE69027220T2 (de) | Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen | |
| DE19737348C2 (de) | Neue Clindamycin und Clotrimazol enthaltende pharmazeutische Zusammensetzung | |
| DE60132441T2 (de) | Extrakt aus einer pflanze der spezies olea europaea als inhibitor der no-synthase und verwendungen | |
| DE60034898T2 (de) | Antiallergische Zusammensetzung, die OLIGOSACCHARIDe und eine Saponine oder eine basische Aminosäure enthält, zur topischen Verabreichung oder Inhalation | |
| DE3784695T2 (de) | Gebrauch von Gramineenextrakten als Arzneimittel. | |
| DE69825279T2 (de) | Verwendung von glukosamin und glukosaminderivaten zur schnellen linderung von juckreiz oder lokalisiertem schmerz | |
| DE69005860T2 (de) | Verwendung von 5'-Deoxy-5'-methylthioadenosin S-adenosylmethionin und dessen Salzen zur Herstellung von Seborrhea vermindernden Arzneimitteln. | |
| DE69313261T2 (de) | Verwendung von LACTOFERRIN zur Herstellung eines THERAPEUTISCHEN MITTELS zur Behandlung von RHEUMATISMUS | |
| DE69914957T2 (de) | Nicht-festes topisch anzuwendendes arzneimittel enthaltend glyzerol und alchemilla vulgaris extrakt | |
| DE1917283C3 (de) | Herstellung antimikrobieller Präparate | |
| DE69328102T2 (de) | Verwendung von gift aus hautflüglern (hymenopteren) zur herstellung eines medikamentes zur behandlung von infektionen durch dna-viren | |
| DE60212842T2 (de) | Dermatologische zusammensetzungen, die nikotinsäure oder nikotinsäureamid und sphingoid-base enthalten | |
| DE2720420A1 (de) | Wirkstoffkombination gegen sonnenerythem und diese enthaltendes arzneimittel | |
| EP2120953B1 (de) | Zubereitungen für die topische behandlung von hauterkrankungen | |
| DE202007004981U1 (de) | Zusammensetzung, insbesondere für die topische Behandlung von Hauterkrankungen | |
| EP1131101B1 (de) | Khellin-zubereitung und deren verwendung zur topischen therapie | |
| EP0016239B1 (de) | Kosmetisches Haar- und Hautpflegemittel und dessen Herstellung | |
| DE2757024A1 (de) | Kosmetisches haar- und hautpflegemittel | |
| Vena et al. | Efficacy and Safety of Bifonazole (BAY h 4502) in Patients with Pityriasis versicolor and Tinea cruris/Zur Wirksamkeit und Verträglichkeit von Bifonazol (BAY h 4502) bei Patienten mit Pityriasis versicolor und Tinea inguinalis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |